Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.

British journal of clinical pharmacology - 1 Mar 2012

Lacut Karine, Ayme-Dietrich Estelle, Gourhant Lenaick, Poulhazan Elise, Andro Marion, Becquemont Laurent, Mottier Dominique, Le Gal Gregoire, Verstuyft Celine

Abstract excerpt

AIM: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9) and of a key pharmacologic target of vitamin K antagonists, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to coumarin derivatives. The role of these variants in fluindione response is unknown. Our aim was to assess whether genetic factors contribute to the variability in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P450 Family 4

Share to Epoxide Hydrolases

Share to International Normalized Ratio

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Source

Open in PubMed Open full text

Identifiers

PMID: 21883387
DOI: 10.1111/j.1365-2125.2011.04095.x
PMCID: PMC3370347

Genes

VKORC1
EPHX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.PMID 21883387Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.Semantic proximity Read ↗

Genetic determinants of response to warfarin during initial anticoagulation.Semantic proximity Read ↗

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.Semantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.Semantic proximity Read ↗

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.Semantic proximity Read ↗

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].Semantic proximity Read ↗

CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation.Semantic proximity Read ↗

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.Semantic proximity Read ↗

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.